Dermata Therapeutics Inc (DRMA)

Dermata Therapeutics Inc (DRMA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.6M; returns 1 day -9.6%, 1 week -9.2%, 1 year -81.3%.

Dermata Therapeutics Inc. (DRMA) is a clinical-stage biotechnology company focused on developing and commercializing products for various skin diseases and aesthetic skin conditions. Their lead product candidate, DMT310 (also known as XYNGARI™), is derived from their Spongilla platform technology and is being developed for the once-weekly treatment of moderate-to-severe acne.

Groups DRMA belongs to

• Clinical Stage Biotech
• Dermatology
• Biotechnology
• Healthcare
• Clinical Stage
• Biopharmaceutical
• Life Sciences
• Over-the-Counter Drugs
• Strategic Pivot
• Beauty Products

DRMA financial model: income statement, cash flow and balance sheet